Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRima M. SalibaIKIndreshpal KaurPKPartow Kebriaei

Discussion

Loading...

Member takes

Overview

Analysis reveals that CD34+/TNC ratio predicts outcomes in AML/MDS patients receiving allogeneic stem cell transplantation with cyclophosphamide prophylaxis.

Key Points

  • Progression-free survival rates were notably different across CD34+/TNC ratio groups, highlighting the predictive value of this marker.
  • Patients with low CD34+/TNC ratios showed a significant increase in relapse risk, underscoring its relevance in treatment planning.
  • Allogeneic stem cell transplantation was performed on patients with hematologic malignancies, confirming the importance of graft composition for patient outcomes.
  • Complications related to graft-versus-host disease differed by CD34+/TNC ratio, suggesting tailored post-transplant strategies may be necessary.

Cite This Study

Saliba et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236dba0https://doi.org/10.1182/blood-2025-5994
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post-transplant monitoring of multiparameter flow-cytometry (MFC)-based measurable residual disease (MRD) assessment combined with T-cell chimerism following allogeneic stem cell transplantation (HCT) in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)2025
  2. 2Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025
  3. 3Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.2025
  4. 4Outcomes after bone marrow versus peripheral blood mismatched unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis2025
  5. 5Impact CD34+ cell doses and allograft composition on acute graft-versus-host disease: A single-center prospective cohort study2025